Literature DB >> 19767510

The thymus-independent immunity conferred by a pneumococcal polysaccharide is mediated by long-lived plasma cells.

Morgan Taillardet1, Ghina Haffar, Paul Mondière, Marie-Jeanne Asensio, Hanane Gheit, Nicolas Burdin, Thierry Defrance, Laurent Genestier.   

Abstract

It was recently shown that bacterial thymus-independent (TI) antigens confer long-lasting immunity and generate memory B lymphocytes. However, reactivation of TI memory B cells is repressed in immunocompetent mice, thus raising the issue of the mechanism whereby TI vaccines confer immune protection. Here, we propose an explanation to this apparent paradox by showing that a Streptococcus pneumoniae capsular polysaccharide (PS) generates long-lived bone marrow (BM) plasma cells which frequency can be increased by CpG oligodeoxynucleotides (ODNs). The adjuvant effect of CpG ODNs on the PS3 Ab response is directly targeted to B cells and does not involve B-1a cells. We also demonstrated that BM plasma cells generated in response to the thymus-dependent (TD) form of the PS vaccine have a higher secretion capacity than those produced after immunization with the CpG-adjuvanted PS vaccine. Finally, we show that the PS-specific BM plasma cell compartment is sufficient to confer full protection of vaccinated mice against S pneumoniae infection. Altogether, our results show that TI antigens like their TD counterparts can generate both the lymphoid and the plasma cell component of B-cell memory. They also provide a framework for the improvement and widespread usage of TI vaccines.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19767510     DOI: 10.1182/blood-2009-01-200014

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  44 in total

1.  Viral Persistence Induces Antibody Inflation without Altering Antibody Avidity.

Authors:  Suzanne P M Welten; Anke Redeker; René E M Toes; Ramon Arens
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

2.  Programmed cell death 1 suppresses B-1b cell expansion and long-lived IgG production in response to T cell-independent type 2 antigens.

Authors:  Karen M Haas
Journal:  J Immunol       Date:  2011-10-14       Impact factor: 5.422

Review 3.  Here, There, and Anywhere? Arguments for and against the Physical Plasma Cell Survival Niche.

Authors:  Joel R Wilmore; David Allman
Journal:  J Immunol       Date:  2017-08-01       Impact factor: 5.422

Review 4.  Antibody persistence and T-cell balance: two key factors confronting HIV vaccine development.

Authors:  George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2014-10-27       Impact factor: 11.205

5.  Low hemagglutinin antigen dose influenza vaccines adjuvanted with AS03 alter the long-term immune responses in BALB/c mice.

Authors:  Karen K Yam; Angela Brewer; Virginie Bleau; Édith Beaulieu; Corey P Mallett; Brian J Ward
Journal:  Hum Vaccin Immunother       Date:  2016-10-21       Impact factor: 3.452

6.  IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine.

Authors:  Sanghita Sarkar; Michael S Piepenbrink; Madhubanti Basu; Juilee Thakar; Michael C Keefer; Ann J Hessell; Nancy L Haigwood; James J Kobie
Journal:  Vaccine       Date:  2019-03-27       Impact factor: 3.641

Review 7.  Innate B cell helpers reveal novel types of antibody responses.

Authors:  Carola G Vinuesa; Pheh-Ping Chang
Journal:  Nat Immunol       Date:  2013-01-18       Impact factor: 25.606

8.  Timing of Toll-like receptor 9 agonist administration in pneumococcal vaccination impacts both humoral and cellular immune responses as well as nasopharyngeal colonization in mice.

Authors:  Katrine M Jensen; Jesper Melchjorsen; Frederik Dagnaes-Hansen; Uffe B S Sørensen; Rune R Laursen; Lars Østergaard; Ole S Søgaard; Martin Tolstrup
Journal:  Infect Immun       Date:  2012-02-27       Impact factor: 3.441

9.  Immunogenicity of meningococcal polysaccharide ACWY vaccine in primary immunized or revaccinated adults.

Authors:  C Ferlito; R Biselli; M S Cattaruzza; R Teloni; S Mariotti; E Tomao; G Salerno; M S Peragallo; P Lulli; S Caporuscio; A Autore; G Bizzarro; V Germano; M I Biondo; A Picchianti Diamanti; S Salemi; R Nisini; R D'Amelio
Journal:  Clin Exp Immunol       Date:  2018-09-20       Impact factor: 4.330

Review 10.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.